|  |  | 

India Top Headlines

2DG Approved for Emergency Use as Add-On Therapy for Covid-19 Patients: DRDO | India News


NEW DELHI: The Defense Research and Development Organization (DRDO) said Tuesday that the anti-Covid drug 2DG is
approved for emergency use as an adjunct therapy to standard of care in treating coronavirus patients in hospital settings.
The DRDO said that the anti-Covid drug 2DG can now be administered to Covid 19 patients under the care and prescription of doctors.
DRDO also issued some important guidelines regarding its anti-Covid -19 drug.
“Ideally, doctors should prescribe 2DG as soon as possible for moderate to severe Covid patients for a maximum duration of up to 10 days,” he said.
DRDO further said that patients with uncontrolled diabetes, severe heart problems, ARDS, severe liver and kidney failure have not yet been studied with 2DG and therefore caution should be exercised.
2DG should not be administered to pregnant and lactating women or to patients under 18 years of age. “Patients and assistants who request the hospital are encouraged to contact Dr. Reddy’s laboratory in Hyderabad for drug delivery at email: [email protected],” he added.
The first batch of DRDO’s anti-Covid-19 drug was launched on May 17 by Defense Minister Rajnath Singh and Health Minister Dr Harsh Vardhan after the Comptroller General of Drugs of India allow the authorization of emergency use of 2-deoxy-D-glucose (2 -DG), an antiviral drug as an add-on therapy for patients with moderate to severe coronavirus.
In April last year, when the pandemic broke out, scientists from the Institute of Nuclear Medicine and Allied Sciences (INMAS), a DRDO laboratory, conducted laboratory experiments with the help of the Center for Cell and Molecular Biology (CCMB), Hyderabad in collaboration with DRL and discovered that this molecule works effectively against the SARS-CoV-2 virus and inhibits viral growth.
The medicine 2-DG comes as a powder in the sachet, which is taken by mouth by dissolving it in water.
It accumulates in cells infected by the virus and prevents virus growth by stopping viral synthesis and energy production. Its selective accumulation in virus-infected cells makes this drug unique. The drug reportedly reduces a patient’s average recovery time by two and a half days and oxygen demand by as much as 40 percent, the Union Health Ministry said.

Reference page